-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Initiates Coverage On Kymera Therapeutics with Buy Rating, Announces Price Target of $52

Benzinga·03/13/2025 13:42:26
Listen to the news
Citigroup analyst Geoff Meacham initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Buy rating and announces Price Target of $52.